NOVAVAX
(NASDAQ: NVAX)

Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.

8.440 s

+0.400 (+4.98%)
Range 8.000 - 8.500   (6.25%)
Open 8.060
Previous Close 8.040
Bid Price 8.030
Bid Volume 8
Ask Price 8.010
Ask Volume 22
Volume 1,701,954
Value -
Remark s
Delayed prices. Updated at 23 Nov 2024 00:40.
Data powered by
View All Events

About NOVAVAX INC

Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.

Loading Chart...

Please login to view stock data and analysis